Cargando…

Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study

OBJECTIVES: Drug interactions, poor adherence to medication and high-risk sexual behaviour may occur in individuals with HIV using recreational drugs. Thus, we aimed to assess the prevalence of recreational drugs use and to explore its clinical impact in HIV patients on treatment. METHODS: Observati...

Descripción completa

Detalles Bibliográficos
Autores principales: Garin, Noe, Zurita, Beatriz, Velasco, Cesar, Feliu, Anna, Gutierrez, Mar, Masip, Montserrat, Mangues, M Antonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253545/
https://www.ncbi.nlm.nih.gov/pubmed/28100565
http://dx.doi.org/10.1136/bmjopen-2016-014105
_version_ 1782498178552037376
author Garin, Noe
Zurita, Beatriz
Velasco, Cesar
Feliu, Anna
Gutierrez, Mar
Masip, Montserrat
Mangues, M Antonia
author_facet Garin, Noe
Zurita, Beatriz
Velasco, Cesar
Feliu, Anna
Gutierrez, Mar
Masip, Montserrat
Mangues, M Antonia
author_sort Garin, Noe
collection PubMed
description OBJECTIVES: Drug interactions, poor adherence to medication and high-risk sexual behaviour may occur in individuals with HIV using recreational drugs. Thus, we aimed to assess the prevalence of recreational drugs use and to explore its clinical impact in HIV patients on treatment. METHODS: Observational, cross sectional, study conducted in a 700 bed university hospital, Barcelona, Spain. A total of 208 adults living with HIV on treatment were included. A questionnaire was administered by clinical pharmacists, including evaluation of sociodemographic variables, past 12-month drug consumption, adherence to antiretrovirals (Simplified Medication Adherence Questionnaire) and high-risk sexual behaviour (condomless sex/multiple partners). Additional data were obtained from clinical records. Recreational drug-antiretroviral interactions were checked in reference databases. Prevalence was calculated for 5% precision and 95% CI. Crude and adjusted binary logistic regressions were performed to identify associations between recreational drug use and adherence problems, and between recreational drug use and high-risk sexual behaviour. RESULTS: From the overall sample, 92 participants (44.2%) consumed recreational drugs over the past 1 year. Of these, 44 (48.8%) had used different types of recreational drugs in this period. We detected 11 recreational substances, including sildenafil and nitrites. The most consumed drugs were: cannabis (68.5%), cocaine (45.5%), nitrites (31.5%), sildenafil (28.3) and ecstasy (19.6%). Relevant interactions occurred in 46 (50%) of the individuals consuming drugs. Recreational drug consumption was found to be related to adherence problems with antiretrovirals (OR: 2.51 (95% CI 1.32 to 4.77) p=0.005) and high-risk sexual behaviour (OR: 2.81 (95% CI 1.47 to 5.39) p=0.002). CONCLUSIONS: Recreational drugs are frequently used by HIV patients on treatment. Classical drugs and new substances consumed in sexual context are usual. Recreational drug consumption interferes with several clinical outcomes, including potentially relevant interactions between drugs and antiretrovirals, adherence problems and high-risk sexual behaviour. Thus, there is the urgent need of implementing patient-centred care involving recreational drug consumption.
format Online
Article
Text
id pubmed-5253545
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-52535452017-01-25 Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study Garin, Noe Zurita, Beatriz Velasco, Cesar Feliu, Anna Gutierrez, Mar Masip, Montserrat Mangues, M Antonia BMJ Open HIV/AIDS OBJECTIVES: Drug interactions, poor adherence to medication and high-risk sexual behaviour may occur in individuals with HIV using recreational drugs. Thus, we aimed to assess the prevalence of recreational drugs use and to explore its clinical impact in HIV patients on treatment. METHODS: Observational, cross sectional, study conducted in a 700 bed university hospital, Barcelona, Spain. A total of 208 adults living with HIV on treatment were included. A questionnaire was administered by clinical pharmacists, including evaluation of sociodemographic variables, past 12-month drug consumption, adherence to antiretrovirals (Simplified Medication Adherence Questionnaire) and high-risk sexual behaviour (condomless sex/multiple partners). Additional data were obtained from clinical records. Recreational drug-antiretroviral interactions were checked in reference databases. Prevalence was calculated for 5% precision and 95% CI. Crude and adjusted binary logistic regressions were performed to identify associations between recreational drug use and adherence problems, and between recreational drug use and high-risk sexual behaviour. RESULTS: From the overall sample, 92 participants (44.2%) consumed recreational drugs over the past 1 year. Of these, 44 (48.8%) had used different types of recreational drugs in this period. We detected 11 recreational substances, including sildenafil and nitrites. The most consumed drugs were: cannabis (68.5%), cocaine (45.5%), nitrites (31.5%), sildenafil (28.3) and ecstasy (19.6%). Relevant interactions occurred in 46 (50%) of the individuals consuming drugs. Recreational drug consumption was found to be related to adherence problems with antiretrovirals (OR: 2.51 (95% CI 1.32 to 4.77) p=0.005) and high-risk sexual behaviour (OR: 2.81 (95% CI 1.47 to 5.39) p=0.002). CONCLUSIONS: Recreational drugs are frequently used by HIV patients on treatment. Classical drugs and new substances consumed in sexual context are usual. Recreational drug consumption interferes with several clinical outcomes, including potentially relevant interactions between drugs and antiretrovirals, adherence problems and high-risk sexual behaviour. Thus, there is the urgent need of implementing patient-centred care involving recreational drug consumption. BMJ Publishing Group 2017-01-18 /pmc/articles/PMC5253545/ /pubmed/28100565 http://dx.doi.org/10.1136/bmjopen-2016-014105 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle HIV/AIDS
Garin, Noe
Zurita, Beatriz
Velasco, Cesar
Feliu, Anna
Gutierrez, Mar
Masip, Montserrat
Mangues, M Antonia
Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study
title Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study
title_full Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study
title_fullStr Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study
title_full_unstemmed Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study
title_short Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study
title_sort prevalence and clinical impact of recreational drug consumption in people living with hiv on treatment: a cross-sectional study
topic HIV/AIDS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253545/
https://www.ncbi.nlm.nih.gov/pubmed/28100565
http://dx.doi.org/10.1136/bmjopen-2016-014105
work_keys_str_mv AT garinnoe prevalenceandclinicalimpactofrecreationaldrugconsumptioninpeoplelivingwithhivontreatmentacrosssectionalstudy
AT zuritabeatriz prevalenceandclinicalimpactofrecreationaldrugconsumptioninpeoplelivingwithhivontreatmentacrosssectionalstudy
AT velascocesar prevalenceandclinicalimpactofrecreationaldrugconsumptioninpeoplelivingwithhivontreatmentacrosssectionalstudy
AT feliuanna prevalenceandclinicalimpactofrecreationaldrugconsumptioninpeoplelivingwithhivontreatmentacrosssectionalstudy
AT gutierrezmar prevalenceandclinicalimpactofrecreationaldrugconsumptioninpeoplelivingwithhivontreatmentacrosssectionalstudy
AT masipmontserrat prevalenceandclinicalimpactofrecreationaldrugconsumptioninpeoplelivingwithhivontreatmentacrosssectionalstudy
AT manguesmantonia prevalenceandclinicalimpactofrecreationaldrugconsumptioninpeoplelivingwithhivontreatmentacrosssectionalstudy